Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Clasificación en acciones #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Precio por acción
$0.6
Última sincronización: 2024-08-14
Capitalización bursátil
$2.09M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
SG
Comercio ASLAN Pharmaceuticals Limited (ASLN)

Categoría

Healthcare
Ganancias de ASLAN Pharmaceuticals Limited (ASLN)
Ganancias en Mar 2024 TTM: $-34.90M
Secondo gli ultimi rapporti finanziari di ASLAN Pharmaceuticals Limited, gli utili attuali della società sono $-34.90M. Nel 2022, la società ha registrato un utile di $-51.28M, una disminución en comparación con agli utili del 2021, che erano di $-31.59M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de ASLAN Pharmaceuticals Limited desde 2014 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-34.90M -20.84%
2023 $-44.09M -14.03%
2022 $-51.28M 62.34%
2021 $-31.59M 86.14%
2020 $-16.97M -63.63%
2019 $-46.66M 10.64%
2018 $-42.17M 3.58%
2017 $-40.71M 352.17%
2016 $-9.00M -32.43%
2015 $-13.33M 80.95%
2014 $-7.36M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -15,214.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,689.14%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -8,712.20%
BE